We are interested in whole-body radiomics for stratification of patients with different types of lymphoma using Fluorodeoxyglucose PET/CT scans. In particular, we have contributed to the validation of the prognostic value of a simple radiomic biomarker, the total metabolically active tumour volume (TMTV). In addition, we introduced a completely original biomarker that reflects the dissemination of the disease, and showed not only its prognostic value, but also its complementarity with TMTV. We are validating methods for the automatic calculation of these prognostic biomarkers and are seeking to complete them in order to improve the quality of the stratification.
People involved in the laboratory: Anne-Ségolène Cottereau (MD, PhD student in science), Louis Rebaud (PhD student), Kibrom Girum (post-doctoral student), Christophe Nioche, Irène Buvat
The work is partly supported by Siemens Healthineers and by the EU as part of the HOLY2020 project.